适应症-话题@MedSci

#适应症#

219篇内容 | 3062人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1336782, encodeId=a27b1336e823d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=CHMP对伊布替尼在欧洲两种适应症扩大持积极态度, objectType=article, longId=174499, objectId=df1f1e44992a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df1f1e44992a, replyNumber=0, likeNumber=66, createdTime=2019-07-01, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df1f1e44992a, moduleTitle=CHMP对伊布替尼在欧洲两种适应症扩大持积极态度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df1f1e44992a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336781, encodeId=e3541336e81df, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA扩大了Soliris的适应症以治疗视神经脊髓炎谱系疾病, objectType=article, longId=174422, objectId=99fb1e442218, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99fb1e442218, replyNumber=0, likeNumber=61, createdTime=2019-06-30, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99fb1e442218, moduleTitle=FDA扩大了Soliris的适应症以治疗视神经脊髓炎谱系疾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99fb1e442218)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336780, encodeId=737e1336e80ab, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=RTOR项目比优先审评还快！7个肿瘤药新适应症已获批, objectType=article, longId=167026, objectId=6ba316e0263d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ba316e0263d, replyNumber=0, likeNumber=78, createdTime=2019-05-29, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ba316e0263d, moduleTitle=RTOR项目比优先审评还快！7个肿瘤药新适应症已获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ba316e0263d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336779, encodeId=e40b1336e7975, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗, objectType=article, longId=165891, objectId=11a416589183, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11a416589183, replyNumber=0, likeNumber=55, createdTime=2019-05-13, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11a416589183, moduleTitle=FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11a416589183)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336778, encodeId=86c91336e7899, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=PD-1正在触碰超适应症的红线，违规用药但治疗有效的局面如何破, objectType=article, longId=165138, objectId=a4f3165138b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4f3165138b0, replyNumber=0, likeNumber=64, createdTime=2019-04-30, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4f3165138b0, moduleTitle=PD-1正在触碰超适应症的红线，违规用药但治疗有效的局面如何破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4f3165138b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336777, encodeId=bc5b1336e7717, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA宣布将辉瑞的Ibrance在转移性乳腺癌中的适应症扩展至男性患者, objectType=article, longId=163910, objectId=419e163910bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=419e163910bc, replyNumber=0, likeNumber=55, createdTime=2019-04-10, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=419e163910bc, moduleTitle=FDA宣布将辉瑞的Ibrance在转移性乳腺癌中的适应症扩展至男性患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=419e163910bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336776, encodeId=57261336e7676, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=刚刚，Keytruda在中国获批新适应症，一线治疗非鳞状NSCLC, objectType=article, longId=163233, objectId=c8c0163233da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8c0163233da, replyNumber=0, likeNumber=65, createdTime=2019-03-31, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8c0163233da, moduleTitle=刚刚，Keytruda在中国获批新适应症，一线治疗非鳞状NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8c0163233da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336775, encodeId=f2cb1336e7529, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=从FDA批准的PD-(L)1类药物适应症看中国肿瘤免疫药物开发进展, objectType=article, longId=161087, objectId=39d816108ef7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39d816108ef7, replyNumber=0, likeNumber=65, createdTime=2019-02-27, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39d816108ef7, moduleTitle=从FDA批准的PD-(L)1类药物适应症看中国肿瘤免疫药物开发进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39d816108ef7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336774, encodeId=be101336e7451, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=英国NICE推荐帕妥珠单抗Perjeta用于治疗新的乳腺癌适应症, objectType=article, longId=160404, objectId=3b0e1604041d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b0e1604041d, replyNumber=0, likeNumber=104, createdTime=2019-02-20, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b0e1604041d, moduleTitle=英国NICE推荐帕妥珠单抗Perjeta用于治疗新的乳腺癌适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b0e1604041d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336773, encodeId=cded1336e73a8, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=2018年中国新药加速上市很多适应症药物从无到有, objectType=article, longId=159176, objectId=0b5b1591e6de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b5b1591e6de, replyNumber=0, likeNumber=76, createdTime=2019-01-31, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b5b1591e6de, moduleTitle=2018年中国新药加速上市很多适应症药物从无到有, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b5b1591e6de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336772, encodeId=2f5e1336e72b3, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=Xolair预填充注射器获得欧盟委员会批准用于所有适应症, objectType=article, longId=155809, objectId=42c4155809a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42c4155809a0, replyNumber=0, likeNumber=52, createdTime=2018-12-16, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42c4155809a0, moduleTitle=Xolair预填充注射器获得欧盟委员会批准用于所有适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42c4155809a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336771, encodeId=227a1336e714e, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=已上市抗肿瘤药物增加新适应症技术指导原则, objectType=article, longId=155111, objectId=18ff1551117c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18ff1551117c, replyNumber=0, likeNumber=56, createdTime=2018-12-06, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18ff1551117c, moduleTitle=已上市抗肿瘤药物增加新适应症技术指导原则, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18ff1551117c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336770, encodeId=6ed01336e708d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=新型降糖药利时敏新适应症在华获批, objectType=article, longId=154279, objectId=6ed11542e9f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ed11542e9f7, replyNumber=0, likeNumber=66, createdTime=2018-11-25, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ed11542e9f7, moduleTitle=新型降糖药利时敏新适应症在华获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ed11542e9f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336769, encodeId=cdc61336e694d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=赛诺菲中国糖尿病产品线再添“新军”，新型降糖药利时敏®新适应症在华获批, objectType=article, longId=154276, objectId=ba471542e607, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba471542e607, replyNumber=0, likeNumber=79, createdTime=2018-11-25, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba471542e607, moduleTitle=赛诺菲中国糖尿病产品线再添“新军”，新型降糖药利时敏®新适应症在华获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba471542e607)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336768, encodeId=dc541336e68e2, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=强生公司寻求在欧洲扩大伊布替尼的适应症, objectType=article, longId=153631, objectId=eeed153631ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eeed153631ca, replyNumber=0, likeNumber=69, createdTime=2018-11-17, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eeed153631ca, moduleTitle=强生公司寻求在欧洲扩大伊布替尼的适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eeed153631ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336767, encodeId=623b1336e6787, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=重磅！贝伐珠单抗适应症扩展获批!, objectType=article, longId=153397, objectId=9c6815339e85, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c6815339e85, replyNumber=0, likeNumber=80, createdTime=2018-11-15, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c6815339e85, moduleTitle=重磅！贝伐珠单抗适应症扩展获批!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c6815339e85)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336766, encodeId=bf1f1336e6631, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=J Hepatol：DAA治疗对肝移植的影响：对适应症和结果演变的影响, objectType=article, longId=149472, objectId=1bf71494e28c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bf71494e28c, replyNumber=0, likeNumber=110, createdTime=2018-09-25, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bf71494e28c, moduleTitle=J Hepatol：DAA治疗对肝移植的影响：对适应症和结果演变的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bf71494e28c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336765, encodeId=55ac1336e6520, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=美国食品药品监督管理局批准Opdivo®新适应症成为全球近20年来用于经治小细胞肺癌的新药, objectType=article, longId=147166, objectId=a7ea14e16667, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7ea14e16667, replyNumber=0, likeNumber=82, createdTime=2018-08-23, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7ea14e16667, moduleTitle=美国食品药品监督管理局批准Opdivo®新适应症成为全球近20年来用于经治小细胞肺癌的新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7ea14e16667)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336764, encodeId=8ac81336e649a, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=K药今日正式登陆中国，新适应症加速获批, objectType=article, longId=147144, objectId=0a7d14e14421, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a7d14e14421, replyNumber=0, likeNumber=61, createdTime=2018-08-22, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a7d14e14421, moduleTitle=K药今日正式登陆中国，新适应症加速获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a7d14e14421)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336763, encodeId=b45d1336e6333, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=西安杨森旗下亿珂®获批适应症扩展用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤, objectType=article, longId=144842, objectId=fd5514484242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd5514484242, replyNumber=0, likeNumber=70, createdTime=2018-07-22, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd5514484242, moduleTitle=西安杨森旗下亿珂®获批适应症扩展用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd5514484242)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

适应症

2020-05-29

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

CHMP对伊布替尼在欧洲两种适应症扩大持积极态度

2019-07-01

仁者大医 (审核中...)

前往app查看评论内容

#适应症#

FDA扩大了Soliris的适应症以治疗视神经脊髓炎谱系疾病

2019-06-30

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

RTOR项目比优先审评还快！7个肿瘤药新适应症已获批

2019-05-29

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗

2019-05-13

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

PD-1正在触碰超适应症的红线，违规用药但治疗有效的局面如何破

2019-04-30

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

FDA宣布将辉瑞的Ibrance在转移性乳腺癌中的适应症扩展至男性患者

2019-04-10

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

刚刚，Keytruda在中国获批新适应症，一线治疗非鳞状NSCLC

2019-03-31

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

从FDA批准的PD-(L)1类药物适应症看中国肿瘤免疫药物开发进展

2019-02-27

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

英国NICE推荐帕妥珠单抗Perjeta用于治疗新的乳腺癌适应症

2019-02-20

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

2018年中国新药加速上市很多适应症药物从无到有

2019-01-31

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

Xolair预填充注射器获得欧盟委员会批准用于所有适应症

2018-12-16

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

已上市抗肿瘤药物增加新适应症技术指导原则

2018-12-06

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

新型降糖药利时敏新适应症在华获批

2018-11-25

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

赛诺菲中国糖尿病产品线再添“新军”，新型降糖药利时敏®新适应症在华获批

2018-11-25

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

强生公司寻求在欧洲扩大伊布替尼的适应症

2018-11-17

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

重磅！贝伐珠单抗适应症扩展获批!

2018-11-15

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

J Hepatol：DAA治疗对肝移植的影响：对适应症和结果演变的影响

2018-09-25

柳叶一刀 (审核中...)

前往app查看评论内容

#适应症#

美国食品药品监督管理局批准Opdivo®新适应症成为全球近20年来用于经治小细胞肺癌的新药

2018-08-23

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

K药今日正式登陆中国，新适应症加速获批

2018-08-22

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

西安杨森旗下亿珂®获批适应症扩展用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤

2018-07-22

科室
- - 订阅+
  - 更多科室
工具
服务